NOVOCURE LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.03 USD | +3.22% |
|
+25.82% | +7.37% |
| May. 02 | NovoCure Shares Steady After Reporting Narrower Q1 Loss, Higher Revenue | MT |
| May. 02 | BioPharma Credit Enters $400 Million Loan Agreement with Novocure Luxembourg | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 8,340 | 17,615 | 7,795 | 7,698 | 1,595 | 1,725 | - | - |
| Enterprise Value (EV) 1 | 8,312 | 17,810 | 8,148 | 8,148 | 1,923 | 1,513 | 1,959 | 1,898 |
| P/E ratio | -1,204 x | 865 x | -134 x | -83.4 x | -7.66 x | -10.1 x | -9.11 x | -9.43 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 23.7 x | 35.6 x | 14.6 x | 14.3 x | 3.13 x | 3.13 x | 2.94 x | 2.59 x |
| EV / Revenue | 23.7 x | 36 x | 15.2 x | 15.1 x | 3.78 x | 2.75 x | 3.34 x | 2.86 x |
| EV / EBITDA | 1,102 x | 450 x | -239 x | -103 x | -8.67 x | -7.9 x | -9.95 x | -10.3 x |
| EV / FCF | 515 x | 212 x | 139 x | 864 x | -19.2 x | -14.3 x | -17.6 x | -18.1 x |
| FCF Yield | 0.19% | 0.47% | 0.72% | 0.12% | -5.22% | -6.98% | -5.69% | -5.53% |
| Price to Book | 38.5 x | 37.2 x | 19 x | - | - | - | - | - |
| Nbr of stocks (in thousands) | 98,969 | 101,797 | 103,819 | 104,950 | 106,861 | 107,611 | - | - |
| Reference price 2 | 84.27 | 173.0 | 75.08 | 73.35 | 14.93 | 16.03 | 16.03 | 16.03 |
| Announcement Date | 2/27/20 | 2/25/21 | 2/24/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 351.3 | 494.4 | 535 | 537.8 | 509.3 | 551.1 | 587.4 | 664.8 |
| EBITDA 1 | 7.546 | 39.55 | -34.08 | -78.9 | -221.9 | -191.5 | -196.9 | -185.2 |
| EBIT 1 | -0.914 | 30.4 | -44.33 | -89.52 | -232.9 | -193.2 | -214.2 | -195.6 |
| Operating Margin | -0.26% | 6.15% | -8.29% | -16.64% | -45.72% | -35.06% | -36.47% | -29.42% |
| Earnings before Tax (EBT) 1 | -8.824 | 18.1 | -52.08 | -81.85 | -191.7 | -157.1 | -187.2 | -175.9 |
| Net income 1 | -7.23 | 19.81 | -58.35 | -92.53 | -207 | -174.4 | -193.5 | -186.8 |
| Net margin | -2.06% | 4.01% | -10.91% | -17.2% | -40.65% | -31.65% | -32.94% | -28.1% |
| EPS 2 | -0.0700 | 0.2000 | -0.5600 | -0.8800 | -1.950 | -1.595 | -1.759 | -1.700 |
| Free Cash Flow 1 | 16.14 | 84.18 | 58.59 | 9.43 | -100.4 | -105.6 | -111.4 | -105 |
| FCF margin | 4.59% | 17.03% | 10.95% | 1.75% | -19.72% | -19.16% | -18.97% | -15.79% |
| FCF Conversion (EBITDA) | 213.82% | 212.84% | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | 424.98% | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/27/20 | 2/25/21 | 2/24/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 133.2 | 137.5 | 140.9 | 131 | 128.4 | 122.2 | 126.1 | 127.3 | 133.8 | 138.5 | 135.4 | 137.4 | 139.9 | 145.9 | 145.7 |
| EBITDA 1 | -20.73 | 1.804 | -18.47 | -21.95 | -40.28 | -57.53 | -59.94 | -55.44 | -48.99 | -38.7 | -51.6 | -52 | -50.42 | -42.87 | -53.94 |
| EBIT 1 | -23.4 | -0.806 | -21.13 | -24.61 | -42.98 | -60.25 | -62.66 | -58.24 | -51.72 | -41.52 | -49.76 | -50.5 | -51.43 | -45.88 | -57.01 |
| Operating Margin | -17.56% | -0.59% | -15% | -18.79% | -33.46% | -49.31% | -49.71% | -45.75% | -38.66% | -29.98% | -36.76% | -36.76% | -36.77% | -31.45% | -39.13% |
| Earnings before Tax (EBT) 1 | -25.57 | -2.515 | -23.36 | -23.42 | -32.56 | -51.08 | -53.9 | -48.22 | -38.53 | -31.64 | -42.04 | -43.55 | -45.77 | -39.51 | -50.63 |
| Net income 1 | -26.46 | -4.647 | -24.01 | -26.58 | -37.3 | -53.06 | -57.42 | -49.48 | -47.08 | -38.76 | -45.07 | -46.43 | -48.22 | -39.51 | -50.63 |
| Net margin | -19.86% | -3.38% | -17.04% | -20.29% | -29.05% | -43.43% | -45.55% | -38.87% | -35.19% | -27.98% | -33.29% | -33.79% | -34.48% | -27.08% | -34.75% |
| EPS 2 | -0.2500 | -0.0400 | -0.2300 | -0.2500 | -0.3600 | -0.5000 | -0.5400 | -0.4600 | -0.4500 | -0.3600 | -0.4102 | -0.4223 | -0.4398 | -0.3750 | -0.4250 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/24/22 | 4/28/22 | 7/28/22 | 10/27/22 | 2/23/23 | 5/4/23 | 7/27/23 | 10/26/23 | 2/22/24 | 5/2/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 195 | 353 | 450 | 328 | - | 234 | 173 |
| Net Cash position 1 | 27.9 | - | - | - | - | 212 | - | - |
| Leverage (Debt/EBITDA) | - | 4.936 x | -10.37 x | -5.706 x | -1.478 x | - | -1.189 x | -0.9353 x |
| Free Cash Flow 1 | 16.1 | 84.2 | 58.6 | 9.43 | -100 | -106 | -111 | -105 |
| ROE (net income / shareholders' equity) | -4.38% | 5.71% | -13.2% | -21.7% | -51.5% | -68.4% | -153% | -420% |
| ROA (Net income/ Total Assets) | -1.77% | 2.59% | -5.33% | -7.94% | -17.7% | -19% | -25.5% | -19.3% |
| Assets 1 | 409.6 | 765.7 | 1,096 | 1,166 | 1,169 | 916 | 758.4 | 966.6 |
| Book Value Per Share | 2.190 | 4.660 | 3.950 | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 10.5 | 15 | 24.2 | 21.4 | 27.1 | 25 | 29.5 | 42 |
| Capex / Sales | 2.98% | 3.03% | 4.52% | 3.97% | 5.32% | 4.54% | 5.02% | 6.32% |
| Announcement Date | 2/27/20 | 2/25/21 | 2/24/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
16.03
USD
Average target price
25.5
USD
Spread / Average Target
+59.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.37% | 1.73B | |
| +73.50% | 12.41B | |
| -19.26% | 7.87B | |
| +2.40% | 6.37B | |
| +3.66% | 5.81B | |
| +11.89% | 5.36B | |
| +37.45% | 4.92B | |
| -19.73% | 4.02B | |
| -35.58% | 2.43B | |
| +0.74% | 2.02B |
- Stock Market
- Equities
- NVCR Stock
- Financials NovoCure Limited